Landscape Capital Management L.L.C. acquired a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 7,717 shares of the company’s stock, valued at approximately $735,000.
Other large investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its position in shares of Rhythm Pharmaceuticals by 36.3% during the second quarter. GAMMA Investing LLC now owns 364 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Rhythm Pharmaceuticals by 106.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 549 shares of the company’s stock valued at $48,000 after buying an additional 283 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in Rhythm Pharmaceuticals during the 2nd quarter worth $51,000. Pinnacle Wealth Planning Services Inc. lifted its position in Rhythm Pharmaceuticals by 894.0% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 666 shares of the company’s stock worth $63,000 after buying an additional 599 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Rhythm Pharmaceuticals by 9.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the company’s stock worth $155,000 after buying an additional 136 shares during the last quarter.
Wall Street Analyst Weigh In
RYTM has been the topic of several research analyst reports. Deutsche Bank started coverage on Rhythm Pharmaceuticals in a report on Friday, August 28th. They issued a “hold” rating and a $120.00 price objective on the stock. Oppenheimer reaffirmed a “market perform” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, November 4th. Needham & Company LLC lowered their target price on Rhythm Pharmaceuticals from $130.00 to $114.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. HC Wainwright boosted their target price on shares of Rhythm Pharmaceuticals from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Finally, Citizens Jmp cut their target price on shares of Rhythm Pharmaceuticals from $166.00 to $160.00 and set a “market outperform” rating for the company in a research report on Friday. Eighteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $141.67.
View Our Latest Stock Report on Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Stock Performance
Rhythm Pharmaceuticals stock opened at $112.36 on Friday. The firm has a 50 day moving average price of $98.08 and a 200 day moving average price of $97.67. Rhythm Pharmaceuticals, Inc. has a 1 year low of $74.50 and a 1 year high of $122.20.
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.10. The company had revenue of $92.13 million during the quarter, compared to analysts’ expectations of $85.56 million. Rhythm Pharmaceuticals had a negative net margin of 69.03% and a negative return on equity of 171.16%. The business’s quarterly revenue was up 79.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.82) EPS. Equities research analysts expect that Rhythm Pharmaceuticals, Inc. will post -4.90 earnings per share for the current fiscal year.
Insider Transactions at Rhythm Pharmaceuticals
In other news, Director Christophe Jean sold 10,000 shares of the company’s stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $109.66, for a total value of $1,096,600.00. Following the completion of the sale, the director owned 11,712 shares of the company’s stock, valued at $1,284,337.92. This represents a 46.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Hunter C. Smith sold 62,774 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $105.46, for a total value of $6,620,146.04. Following the transaction, the chief financial officer directly owned 114,024 shares in the company, valued at $12,024,971.04. This trade represents a 35.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 168,695 shares of company stock worth $18,356,174 over the last ninety days. 5.90% of the stock is owned by insiders.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.
See Also
- Five stocks we like better than Rhythm Pharmaceuticals
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Want to see what other hedge funds are holding RYTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report).
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
